SPRINGWORKS THERAPEUTICS, INC. (SWTX) News
Filter SWTX News Items
SWTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SWTX News Highlights
- SWTX's 30 day story count now stands at 4.
- Over the past 16 days, the trend for SWTX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- AMP, LI and CONN are the most mentioned tickers in articles about SWTX.
Latest SWTX News From Around the Web
Below are the latest news stories about SPRINGWORKS THERAPEUTICS INC that investors may wish to consider to help them evaluate SWTX as an investment opportunity.
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceSTAMFORD, Conn., Dec. 21, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 7:30 a.m. PT. To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company’s website at https: |
SpringWorks Therapeutics announces closing of upsized public offering of common stockMore on SpringWorks Therapeutics |
SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesSTAMFORD, Conn., Dec. 08, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today the closing of its previously announced underwritten public offering of 10,905,171 shares of its common stock at a public offering price of $29.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,422,413 shares of common stock in |
SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common StockSTAMFORD, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today the pricing of an underwritten public offering of 9,482,758 shares of its common stock at a public offering price of $29.00 per share. All of the shares in the offering are being sold by SpringWorks. The gross proceeds from the offering, before deducting underwriting discounts and commissions and |
SpringWorks Therapeutics Announces Proposed Public Offering of Common StockSTAMFORD, Conn., Dec. 04, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that it has commenced an underwritten public offering of $250.0 million of shares of its common stock. All of the shares in the offering will be sold by SpringWorks. In addition, SpringWorks expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares |
SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceSTAMFORD, Conn., Nov. 29, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference, taking place in Miami, Florida on Thursday, November 30, 2023 at 8:45 a.m. ET. To access the live webcast please visit the Events & Presentations page within the Investors & Media section of |
SpringWorks Catapults 19% On A 'Watershed Moment' In Cancer TreatmentSWTX stock soared Tuesday after U.S. regulators signed off on SpringWorks Therapeutics' new cancer treatment for desmoid tumors, Ogsiveo. |
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors– Approval based on positive data from Phase 3 DeFi trial, in which OGSIVEO significantly improved progression-free survival and objective response rate, with rapid and sustained improvements in pain, physical functioning and overall quality of life – – SpringWorks to host conference call tomorrow at 8:00 a.m. ET – A Media Snippet accompanying this announcement is available by clicking on this link. STAMFORD, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), |
SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN– Confirmed objective response rate of 52% in pediatric patients and 41% in adult patients, as assessed by Blinded Independent Central Review – – Mirdametinib treatment resulted in deep and durable responses and significant improvements in key secondary patient-reported outcome measures – – Mirdametinib was generally well tolerated with low rates of Grade 3+ adverse events – – Additional data expected to be presented at medical conference and NDA submission to the U.S. FDA planned in the first h |
SpringWorks Therapeutics Inc (SWTX) Reports Q3 2023 Financial ResultsCompany Continues to Advance its Oncology Pipeline with Key Milestones on the Horizon |